MedPath

NMPA Approvals

Chinese National Medical Products Administration approved drug approval numbers and registration information

National Medical Products Administration
China
166,322 Approvals
Showing 1001 to 1020 of 166,322 approvalsPage 51 of 8317

Iohexol Injection

Approval Number: 国药准字H20253738
Registration: Mar 25, 2025

Paliperidone Extended-Release Tablets

Approval Number: 国药准字H20253743
Registration: Mar 25, 2025

Choline Fenofibrate Sustained-release Capsules

Approval Number: 国药准字H20253684
Registration: Mar 25, 2025

Piracetam Injection

Approval Number: 国药准字H20253688
Registration: Mar 25, 2025

Cefazolin Sodium for Injection

Approval Number: 国药准字HC20250004
Registration: Mar 25, 2025

Iohexol Injection

Approval Number: 国药准字H20253736
Registration: Mar 25, 2025

Rivastigmine Transdermal Patch

Approval Number: 国药准字HJ20200018
Registration: Mar 25, 2025

Thioctic Acid Tablets

Approval Number: 国药准字H20253713
Registration: Mar 25, 2025

Tadalafil Tablets

Approval Number: 国药准字H20253698
Registration: Mar 25, 2025

Glucosamine Sulfate Capsules

Approval Number: 国药准字H20253708
Registration: Mar 25, 2025

Rivaroxaban Tablets

Approval Number: 国药准字H20258040
Registration: Mar 25, 2025

Rivastigmine Transdermal Patch

Approval Number: 国药准字HJ20200019
Registration: Mar 25, 2025

Sodium Bicarbonate Injection

Approval Number: 国药准字H20258043
Registration: Mar 25, 2025

Dronedarone Hydrochloride Tablets

Approval Number: 国药准字H20253735
Registration: Mar 25, 2025

Eldecalcitol Soft Capsules

Approval Number: 国药准字H20253728
Registration: Mar 25, 2025

Rivaroxaban Tablets

Approval Number: 国药准字H20258041
Registration: Mar 25, 2025

Regorafenib Tablets

Approval Number: 国药准字H20253676
Registration: Mar 25, 2025

Olanzapine Tablets

Approval Number: 国药准字H20253703
Registration: Mar 25, 2025

Azilsartan Medoxomil Potassium Tablets

Approval Number: 国药准字H20253695
Registration: Mar 25, 2025

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.